18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience

European Journal of Radiology

Volumn 71, Issue 2, 2009, Pages 242-248

  Ledezma, Carlos J ^a   Chen, Wei ^a   Sai, Victor ^a   Freitas, Bonnie ^a   Cloughesy, Tim ^a   Czernin, Johannes ^a   Pope, Whitney ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F FDOPA; Glioma; Image fusion; Image registration; Magnetic resonance imaging (MRI); PET MRI; Positron emission tomography (PET)

Indexed keywords

18F-FDOPA; FDG PET; FUSION TECHNOLOGY; GLIOMA; LOW-GRADE GLIOMAS; MR SIGNALS; MRI IMAGE; PET/MRI; RECURRENT TUMORS; SENSITIVITY AND SPECIFICITY; TUMOR DETECTION; TUMOR RESECTION;

DIAGNOSIS; IMAGE FUSION; IMAGE REGISTRATION; LABELS; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; ONCOLOGY; POSITRONS; TUMORS;

POSITRON EMISSION TOMOGRAPHY;

3,4 DIHYDROXY 6 FLUOROPHENYLALANINE F 18; FLUORINE 18; GADOLINIUM PENTETATE; PHENYLALANINE DERIVATIVE; UNCLASSIFIED DRUG; 6 FLUORODOPA F 18; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER SURGERY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CRANIOTOMY; DRUG UPTAKE; FEMALE; FOLLOW UP; GLIOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; TUMOR LOCALIZATION; BRAIN TUMOR; IMAGE ENHANCEMENT; IMAGE SUBTRACTION; METHODOLOGY; MIDDLE AGED; PILOT STUDY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ADULT; AGED; BRAIN NEOPLASMS; DIHYDROXYPHENYLALANINE; FEMALE; GLIOMA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE;

EID: 67651236876     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.04.018     Document Type: Article

References (26)

1. Wong T.Z., van der Westhuizen G.J., and Coleman R.E. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 12 (2002) 615-626
2. Weber W.A., Avril N., and Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 175 (1999) 356-373
3. 18F] fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 22 (1987) 360-371
4. Strauss L.G. Fluorine-18 deoxyglucose and false-+ results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23 (1996) 1409-1415
5. Ricci P.E., Karis J.P., Heiserman J.E., et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. AJNR Am J Neuroradiol 19 (1998) 407-413
6. Shreve P.D., Anzai Y., and Wahl R.L. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19 (1999) 61-77
7. Love C., Tomas M.B., Tronco G.G., et al. FDG PET of infection and inflammation. Radiographics 25 (2005) 1357-1368
8. Elsinga P.H., Hatano K., and Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr Med Chem 13 (2006) 2139-2153
9. 18F]fluorodopa positron emission tomographic studies. Mov Disord 5 (1990) 203-213
10. Garnett E.S., Firnau G., and Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 305 (1983) 137-138
11. 11C]methionine. Eur J Nucl Med Mol Imaging 30 (2003) 1561-1567
12. 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47 (2006) 904-911
13. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46 (2005) 1948-1958
14. 18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol 84 (2007) 305-314
15. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46 (2005) 1948-1958
16. Laverman P., Boerman O.C., Corstens F.H., et al. Fluorinated amino acids for tumor imaging with positron emission tomography. Eur J Nucl Med Mol Imaging 29 (2002) 681-690
17. 11C]methionine uptake in brain tumors: initial results of a comparative study. Eur J Nucl Med 27 (2002) 542-549
18. 11C]methionine. Eur J Nucl Med Mol Imaging 30 (2003) 1561-1567
19. 18F]fluoro-L-DOPA. Biochem Pharmacol 62 (2001) 1409-1415
20. 18F]fluoro-l-DOPA kinetics. J Cereb Blood Flow Metab 18 (1998) 43-51
21. 18F]fluoro-L-DOPA and its metabolism in vivo-a critical review. Int J Rad Appl Instrum B 19 (1992) 149-158
22. Ginsberg L.E., Fuller G.N., Hashmi M., et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49 (1998) 436-440
23. Mihara F., Numaguchi Y., Rothman M., et al. Non-enhancing supratentorial malignant astrocytomas: MR features and possible mechanisms. Radiat Med 13 (1995) 11-17
24. Herholz K., Pietrzyk U., Voges J., et al. Correlation of glucose consumption and tumor cell density in astrocytomas: a stereotactic PET study. J Neurosurg 79 (1993) 853-858
25. Wurm G., Parsaei B., Silye R., et al. Distinct supratentorial lesions mimicking cerebral gliomas. Acta Neurochir (Wien) 146 (2004) 19-26
26. Popperl G., Gotz C., Rachinger W., et al. Value of O-(2-[18F] fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Mol Imaging 31 (2004) 1464-1470